Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, today announced that Maureen O’Connell has stepped down from her position as Director and Audit Committee Chair on the Company’s board of directors, effective December 31, 2023.

“I have been part of Filament’s leadership team since its inception and am proud of the Company’s continued progress as a leader in psychedelic drug development. I am confident in the Company’s management team and wish Filament nothing but success going forward.”

-Maureen O’Connell

The Board of Directors and the Company’s management team would like to thank Maureen for her valuable contributions to Filament. Filament CEO Benjamin Lightburn, Dr. Konstantin Adamsky, Jonathan Conlin, and Chris Wagner continue to serve on the Company’s board.

ABOUT FILAMENT HEALTH (OTCQB:FLHLF) (NEO:FH) (FSE:7QS)
Filament Health is a clinical-stage natural psychedelic drug development company. We believe that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and our mission is to see them in the hands of everyone who needs them as soon as possible. Filament’s platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines. We are paving the way with the first-ever natural psychedelic drug candidates.

Original Source